Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gusacitinib - Asana BioSciences

Next Previous
X
Search
Drug Profile

Gusacitinib - Asana BioSciences

Alternative Names: ASN-002

Latest Information Update: 07 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Asana BioSciences
  • Developer Asana BioSciences; Libertas Bio
  • Class Acetonitriles; Antineoplastics; Antirheumatics; Piperidines; Pyridazines; Pyrimidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Eczema
  • Phase II Atopic dermatitis; Chronic lymphocytic leukaemia; Dermatitis; Myelofibrosis; Non-Hodgkin's lymphoma
  • Phase I/II Solid tumours
  • No development reported Rheumatoid arthritis

Most Recent Events

  • 02 Feb 2024 National Institute of Arthritis and Musculoskeletal and Skin Diseases plans a phase I in Systemic lupus erythematosus in USA (PO, Tablet) in February 2024 (NCT06238531)
  • 17 Jul 2023 Phase II development in atopic dermatitis in USA, Canada and Germany (Asana BioSciences pipeline; July 2023)
  • 17 Jul 2023 Phase II development in dermatitis is ongoing in USA, Canada (TrialSpark pipeline; July 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top